In:
Oncology, S. Karger AG, Vol. 90, No. 6 ( 2016), p. 327-338
Kurzfassung:
〈 b 〉 〈 i 〉 Background/Objectives: 〈 /i 〉 〈 /b 〉 CD44 is often expressed in various types of tumor cells and involved in a number of biological behaviors of malignancy. The present study focused on the clinical significance of the expression of CD44st and CD44v6 in non-small cell lung cancer (NSCLC). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The cohort consisted of 261 consecutive patients who had undergone complete resection of NSCLC. CD44 expression was evaluated in surgical specimens by immunohistochemical staining. Serum CD44 levels were determined using a sandwich ELISA (enzyme-linked immunosorbent assay). 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In the immunohistochemical analysis, significant correlations were observed between CD44 expression and clinicopathological factors such as the T factor, N factor, pathological stage, and histological type. The 5-year survival rates according to CD44v6 expression were 65.8 and 80.6% in the higher and lower expression groups, respectively (p = 0.0053). According to ELISA, the group with higher expression of serum CD44v6 also showed a significantly more unfavorable prognosis than the lower expression group (p = 0.014). According to multivariate analysis using these significant variables, serum CD44v6 level was found to be an independent prognostic factor (p = 0.048). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 CD44v6 overexpression and higher serum CD44v6 levels were found to be significantly unfavorable prognostic factors.
Materialart:
Online-Ressource
ISSN:
0030-2414
,
1423-0232
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2016
ZDB Id:
1483096-6
ZDB Id:
250101-6
